Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,295 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Respiratory Disease Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

NCT04948203
View directory record Official record
Conditions
Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions
Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease

NCT03645031
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Neuromuscular Diseases
Interventions
Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 23, 2026, 1:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Related Health and Infection Control Practices Among Dentists

NCT04423770
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
No intervention
Other
Lead sponsor
American Dental Association
Other
Eligibility
18 Years and older
Enrollment
2,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Results available

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

NCT01438853
View directory record Official record
Conditions
Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
TNX-832, Placebo
Biological · Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

NCT02612922
View directory record Official record
Conditions
Influenza
Interventions
Nitazoxanide, Placebo
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years to 65 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Hot Springs, Arkansas • Anaheim, California • Fresno, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 23, 2026, 1:17 AM EDT
Completed No phase listed Observational

Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops

NCT06163690
View directory record Official record
Conditions
Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Long Haul COVID, Long-Haul COVID-19
Interventions
Endourage Targeted Wellness Formula C™, a full hemp flower extract
Combination Product
Lead sponsor
Endourage, LLC
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

NCT05438602
View directory record Official record
Conditions
COVID-19
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir, Placebo for ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
San Francisco, California • Washington D.C., District of Columbia • Doral, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 23, 2026, 1:17 AM EDT
Active, not recruiting No phase listed Observational

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636
View directory record Official record
Conditions
COVID-19, Coronavirus Disease 2019, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Not applicable Interventional Results available

Residential Cleaning of Indoor Air to Protect COPD Patients

NCT03750292
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
HEPAirX air filter, control air filter
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 23, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 23, 2026, 1:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

NCT03694392
View directory record Official record
Conditions
Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, Stroke
Interventions
Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 64 Years
Enrollment
2,776,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 2 Interventional

Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

NCT03805581
View directory record Official record
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Defibrotide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
2 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 23, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

Portable MRI for Pediatric Hypoxic Ischemic Brain Injury

NCT07577336
View directory record Official record
Conditions
Acute Brain Injury, Hypoxia, Brain, Ischemia, Brain, Brain Injuries, Trauma, Brain, Stroke
Interventions
Portable MRI, Scavenged Sample Collection
Device · Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 1:17 AM EDT
Terminated Phase 3 Interventional Results available

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

NCT04348656
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma
Biological
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
16 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 23, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 23, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NCT02370095
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Treprostinil Inhalation Solution, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

NCT04412057
View directory record Official record
Conditions
COVID-19 Pneumonia, Acute Lung Injury, ARDS
Interventions
CERC-002, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Newport Beach, California • Ft. Pierce, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 23, 2026, 1:17 AM EDT
Available No phase listed Expanded access

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

NCT07332338
View directory record Official record
Conditions
Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral
Interventions
REGENECYTE®
Biological
Lead sponsor
StemCyte, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Miami, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 2 Interventional

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

NCT06316843
View directory record Official record
Conditions
Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions
Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo
Drug
Lead sponsor
Bateman Horne Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 23, 2026, 1:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Saliva as Source of Detection for SARS-CoV-2

NCT04424446
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 23, 2026, 1:17 AM EDT
Completed No phase listed Observational

Respiratory Virus Hospitalization Study (FLU 003 Plus)

NCT01056185
View directory record Official record
Conditions
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
18
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 23, 2026, 1:17 AM EDT
Completed Phase 1 Interventional

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

NCT00023296
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Nitric Oxide, INO Pulse - NO Delivery System
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 23, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NCT07535008
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Dental Cleaning, Dental Plaque sampling
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 23, 2026, 1:17 AM EDT